Opinion

Video

Patient with Newly Diagnosed CLL with High-Risk Features

Author(s):

Catherine C. Coombs, MD,Bita Fakhri, MD, MPH

A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.

Video content above is prompted by the following question(s):

  • Please describe your initial impressions of this case. How might you have treated this patient in your practice?
Related Videos
2 experts in this video
2 experts in this video
John M. Burke, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
1 expert in this video
1 expert in this video
Related Content
The OncFive: Top Oncology Articles for the Week of 12/18
December 14th 2024

The OncFive: Top Oncology Articles for the Week of 12/18

Misako Nagasaka, MD, PhD, associate professor, Division of Hematology and Oncology, Division of Medicine, University of California Irvine School of Medicine
December 10th 2024

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com
December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

Matthew Lunning, DO, FACP, associate professor, Division of Oncology & Hematology, associate vice chair, research, Department of Internal Medicine, assistant vice chancellor, clinical research, University of Nebraska Medical Center; Sarah Rutherford, MD, assistant professor, medicine, Division of Hematology/Oncology, Weill Cornell Medicine
April 18th 2024

Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma

B-Cell Malignancies
December 9th 2024

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 8th 2024

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL